IDEPI: Rapid Prediction of HIV-1 Antibody Epitopes and Other Phenotypic Features from Sequence Data Using a Flexible Machine Learning Platform

PLoS Computational Biology

Volumn 10, Issue 9, 2014, Pages

  Hepler, N Lance ^a   Scheffler, Konrad ^b   Weaver, Steven ^b   Murrell, Ben ^b   Richman, Douglas D ^a,c   Burton, Dennis R ^d,e   Poignard, Pascal ^d   Smith, Davey M ^b,c   Kosakovsky Pond, Sergei L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; ARTIFICIAL INTELLIGENCE; DISEASES; DRUG THERAPY; EPITOPES; LEARNING ALGORITHMS; LEARNING SYSTEMS; OPEN SOURCE SOFTWARE; OPEN SYSTEMS;

FLEXIBLE MACHINES; GENETIC BASIS; GENETIC VARIABILITY; LEARNING PLATFORM; MACHINE-LEARNING; NEUTRALISATION; OPEN-SOURCE; PHENOTYPIC FEATURES; RESEARCH EFFORTS; SEQUENCE DATA;

VIRUSES;

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS 1 ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY 10E8; NEUTRALIZING ANTIBODY 8ANC131; NEUTRALIZING ANTIBODY 8ANC195; NEUTRALIZING ANTIBODY PG9; NEUTRALIZING ANTIBODY PGT 121; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN;

ACCURACY; ANTIBIOTIC RESISTANCE; ARTICLE; AUTOMATION; COMPUTER PREDICTION; COMPUTER PROGRAM; GENE LIBRARY; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; MACHINE LEARNING; NONHUMAN; SEQUENCE DATABASE; SIMULATION; SYSTEM ANALYSIS; TROPISM; VIRUS GENE; ALGORITHM; ANTIVIRAL RESISTANCE; BIOLOGY; CHEMISTRY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PHENOTYPE; PROCEDURES; SEQUENCE ANALYSIS; VIROLOGY;

AIDS DEMENTIA COMPLEX; ALGORITHMS; ANTIBODIES, NEUTRALIZING; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MACHINE LEARNING; PHENOTYPE; SEQUENCE ANALYSIS, PROTEIN; SOFTWARE;

EID: 84907588544     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003842     Document Type: Article

References (67)

1. Tang MW, Shafer RW, (2012) HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 72: e1–25.
2. Liu TF, Shafer RW, (2006) Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 42: 1608–18.
3. Poon AFY, Aldous JL, Mathews WC, Kitahata M, Kahn JS, et al. (2011) Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load. PLoS One 6: e21189.
4. Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, et al. (2008) Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 47: 266–85.
5. Zhang J, Rhee SY, Taylor J, Shafer RW, (2005) Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays. J Acquir Immune Defic Syndr 38: 439–44.
6. Frentz D, Boucher CAB, Assel M, De Luca A, Fabbiani M, et al. (2010) Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One 5: e11505.
7. Jiamsakul A, Kantor R, Li PCK, Sirivichayakul S, Sirisanthana T, et al. (2012) Comparison of predicted susceptibility between genotype and virtual phenotype HIV drug resistance interpretation systems among treatment-naive HIV-infected patients in Asia: TASER-M cohort analysis. BMC Res Notes 5: 582.
8. Poon AFY, Kosakovsky Pond SL, Richman DD, Frost SDW, (2007) Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients. J Virol 81: 13598–607.
9. Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, et al. (2010) HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother 54: 4253–61.
10. Melikian GL, Rhee SY, Taylor J, Fessel WJ, Kaufman D, et al. (2012) Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother 56: 2305–13.
11. Garrido C, Villacian J, Zahonero N, Pattery T, Garcia F, et al. (2012) Broad phenotypic crossresistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 56: 2873–8.
12. Van der Borght K, Verheyen A, Feyaerts M, Van Wesenbeeck L, Verlinden Y, et al. (2013) Quantitative prediction of integrase inhibitor resistance from genotype through consensus linear regression modeling. Virol J 10: 8.
13. Zhang J, Hou T, Wang W, Liu JS, (2010) Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance. Proc Natl Acad Sci U S A 107: 1321–6.
14. Yuan Y, Yokoyama M, Maeda Y, Terasawa H, Harada S, et al. (2013) Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc. PLoS One 8: e65115.
15. Prosperi MCF, Altmann A, Rosen-Zvi M, Aharoni E, Borgulya G, et al. (2009) Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Antivir Ther 14: 433–42.
16. Heider D, Senge R, Cheng W, Hüllermeier E, (2013) Multilabel classification for exploiting crossresistance information in HIV-1 drug resistance prediction. Bioinformatics 29: 1946–52.
17. Jessen LE, Hoof I, Lund O, Nielsen M, (2013) SigniSite: Identification of residue-level genotypephenotype correlations in protein multiple sequence alignments. Nucleic Acids Res 41: W286–91.
18. Moore JP, Trkola A, Dragic T, (1997) Co-receptors for HIV-1 entry. Curr Opin Immunol 9: 551–62.
19. Vandekerckhove L, Verhofstede C, Vogelaers D, (2009) Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. J Antimicrob Chemother 63: 1087–96.
20. Philpott SM, (2003) HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res 1: 217–27.
21. de Jong JJ, Goudsmit J, Keulen W, Klaver B, Krone W, et al. (1992) Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol 66: 757–65.
22. Wilkin TJ, Goetz MB, Leduc R, Skowron G, Su Z, et al. (2011) Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clin Infect Dis 52: 925–8.
23. Sánchez V, Masiá M, Robledano C, Padilla S, Ramos JM, et al. (2010) Performance of genotypic algorithms for predicting HIV-1 tropism measured against the enhanced-sensitivity Trofile coreceptor tropism assay. J Clin Microbiol 48: 4135–9.
24. Portsmouth S, Valluri SR, Däumer M, Thiele B, Valdez H, et al. (2013) Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing coreceptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078. Antiviral Res 97: 60–5.
25. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, et al. (1992) Phenotypeassociated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 66: 3183–7.
26. Pillai S, Good B, Richman D, Corbeil J, (2003) A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 19: 145–9.
27. Dybowski JN, Heider D, Hoffmann D, (2010) Prediction of co-receptor usage of HIV-1 from genotype. PLoS Comput Biol 6: e1000743.
28. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, et al. (2003) Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77: 13376–88.
29. Resch W, Hoffman N, Swanstrom R, (2001) Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 288: 51–62.
30. Díez-Fuertes F, Delgado E, Vega Y, Fernández-García A, Cuevas MT, et al. (2013) Improvement of HIV-1 coreceptor tropism prediction by employing selected nucleotide positions of the env gene in a Bayesian network classifier. J Antimicrob Chemother 68: 1471–85.
31. Kumar R, Raghava GPS, (2013) Hybrid approach for predicting coreceptor used by HIV-1 from its V3 loop amino acid sequence. PLoS One 8: e61437.
32. Sander O, Sing T, Sommer I, Low AJ, Cheung PK, et al. (2007) Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Comput Biol 3: e58.
33. Low AJ, Dong W, Chan D, Sing T, Swanstrom R, et al. (2007) Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 21: F17–24.
34. Pillai SK, Pond SLK, Liu Y, Good BM, Strain MC, et al. (2006) Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain 129: 1872–83.
35. Holman AG, Gabuzda D, (2012) A machine learning approach for identifying amino acid signatures in the HIV env gene predictive of dementia. PLoS One 7: e49538.
36. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, et al. (2011) Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog 7: e1002209.
37. Burton DR, Weiss RA, (2010) A boost for HIV vaccine design. Science 329: 770–3.
38. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285–9.
39. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811–7.
40. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466–70.
41. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, et al. (2012) A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 12: 396–407.
42. Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, et al. (2013) Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 20: 804–13.
43. O'Rourke SM, Schweighardt B, Phung P, Fonseca DPAJ, Terry K, et al. (2010) Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J Virol 84: 11200–9.
44. Gnanakaran S, Daniels MG, Bhattacharya T, Lapedes AS, Sethi A, et al. (2010) Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol 6: e1000955.
45. West AP, JrScharf L, Horwitz J, Klein F, Nussenzweig MC, et al. (2013) Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc Natl Acad Sci U S A 110: 10598–603.
46. Chuang GY, Acharya P, Schmidt SD, Yang Y, Louder MK, et al. (2013) Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. J Virol 87: 10047–58.
47. Ferguson AL, Falkowska E, Walker LM, Seaman MS, Burton DR, et al. (2013) Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data. PLoS One 8: e80562.
48. Lacerda M, Moore PL, Ngandu NK, Seaman M, Gray ES, et al. (2013) Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virol J 10: 347.
49. Stanfel LE, (1996) A New Approach to Clustering the Amino Acid. Journal of Theoretical Biology 183: 195–205.
50. Peng H, Long F, Ding C, (2005) Feature selection based on mutual information criteria of max-dependency, max-relevance, and min-redundancy. Pattern Analysis and Machine Intelligence, IEEE Transactions on 27: 1226–1238.
51. Ravich VL, Masso M, Vaisman II, (2011) A combined sequence-structure approach for predicting resistance to the non-nucleoside HIV-1 reverse transcriptase inhibitor Nevirapine. Biophys Chem 153: 168–72.
52. Avila-Ríos S, García-Morales C, Garrido-Rodríguez D, Ormsby CE, Hernández-Juan R, et al. (2011) National prevalence and trends of HIV transmitted drug resistance in Mexico. PLoS One 6: e27812.
53. Cohen J, (1960) A coefficient of agreement for nominal scales. Educational and Psychological Measurement 20: 37–46.
54. Liu L, May S, Richman DD, Hecht FM, Markowitz M, et al. (2008) Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. AIDS 22: 835–9.
55. Cormier EG, Tran DN, Yukhayeva L, Olson WC, Dragic T, (2001) Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol 75: 5541–9.
56. Holman AG, Mefford ME, O'Connor N, Gabuzda D, (2010) HIVBrainSeqDB: a database of annotated HIV envelope sequences from brain and other anatomical sites. AIDS Res Ther 7: 43.
57. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024–7.
58. Kwong PD, Mascola JR, Nabel GJ, (2013) Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol 13: 693–701.
59. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67: 6642–7.
60. Gray ES, Meyers T, Gray G, Montefiori DC, Morris L, (2006) Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med 3: e255.
61. Huang Cc, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025–8.
62. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336–43.
63. Julien JP, Sok D, Khayat R, Lee JH, Doores KJ, et al. (2013) Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 9: e1003342.
64. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, et al. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406–12.
65. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333: 1633–7.
66. Scargle JD, Norris JP, Jackson B, Chiang J, (2013) Studies in Astronomical Time Series Analysis. VI. Bayesian Block Representations. The Astrophysical Journal 764: 167.
67. Ogert RA, Lee MK, Ross W, Buckler-White A, Martin MA, et al. (2001) N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. J Virol 75: 5998–6006.